Order results by:
| Issue | Title | |
| Vol 7, No 2 (2014) | EPIDEMIOLOGIC RESEARCH ON EPILEPSY IN MINSK | Abstract similar documents |
| T. V. Dokukina, T. S. Golubeva, I. V. Matveichuk, M. V. Mahrov, V. M. Loseva, E. V. Krupenkina, S. A. Marchuk | ||
| "... aspects of epilepsy were reviewed. Out-patient visit data collected for the period from 2008 to 2012 ..." | ||
| Vol 9, No 2 (2016) | BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak | ||
| "... приступов (primary generalized tonic-clonic seizures — PGTC) у пациентов с эпилепсией старше 12 лет в ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... statistical monitoring, and results of previous epilepsy burden analysis conducted in the Russian Federation ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT | Abstract similar documents |
| N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova | ||
| Vol 10, No 1 (2017) | PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM | Abstract similar documents |
| N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova | ||
| "... Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y ..." | ||
| Vol 12, No 1 (2019) | Prevalence survey of musculoskeletal and connective tissue disorders in the Russian Federation | Abstract similar documents |
| T. A. Oleynikova, D. N. Pozhidaeva, A. Yu. Oreshko | ||
| "... 2012- 2017. In this, we used the statistical reports on musculoskeletal and connective tissue diseases ..." | ||
| Vol 7, No 1 (2014) | PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY | Abstract similar documents |
| D. V. Blinov | ||
| "... to predict severity and outcome of epilepsy, stroke, traumatic brain injury (TBI) and other neurological ..." | ||
| Vol 5, No 1 (2012) | VI CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» | Abstract similar documents |
| "... and pharmacoepidemiology in Russian Federation», 28-29 of February, 2012, Krasnodar ..." | ||
| Vol 7, No 1 (2014) | CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT | Abstract similar documents |
| I. I. Shteynberg, S. K. Zyryanov, Yu. B. Belousov | ||
| "... the article presents the results of a retrospective study conducted in the period from 2008 ..." | ||
| Vol 5, No 1 (2012) | DYNAMICS OF PREFERENTIAL MAINTENANCE OF CITIZENS WITH ANTIHYPERTENSIVE DRUGS AT THE EXPENSE OF THE REGIONAL BUDGET | Abstract similar documents |
| I. I. Lavrentyeva, A. I. Khokhlov, I. N. Kagramanyan, T. A. Gorokhova | ||
| "... of an arterial hypertension at the expense of the regional budget for 2008-2011 has revealed expansion ..." | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract similar documents |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| "... State Health Care Institution «City Clinical Oncology Dispensary» in 2008-2010 was done ..." | ||
| Vol 6, No 3 (2013) | THE MONITORING RESEARCHES OF HIV/AIDS ON THE BASIS OF THE SITUATION ANALYSIS | Abstract similar documents |
| N. B. Dremova, I. V. Alekseev | ||
| "... of the Central Federal District of Russia for the period 2009-2012. With the application of complex of economic ..." | ||
| Vol 15, No 2 (2022) | Clinical study of real-time polymerase chain reaction test kit for SARS-CoV-2 ribonucleic acids detection | Abstract similar documents |
| M. Yu. Dmitryukova, A. A. Golod, M. E. Senina, A. E. Gushchin | ||
| "... was 100% (95% confidence interval (CI) 95.6–100) for nasal and oropharyngeal swabs and 100% (95% CI 94 ..." | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... breastfeeding. Methods. The cost of providing 100 ml of breast milk (BM) using clinical breast pump and 100 ml ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer | Abstract similar documents |
| Yu. Yu. Petukhova, E. V. Eliseeva, M. V. Volkov, O. N. Li, A. G. Petukhova | ||
| "... rubles. The calculation of resource consumption showed that in the case of a limited budget, 100 ..." | ||
| Vol 13, No 3 (2020) | Parameters for evaluating the main indicators of coloproctological care in the adult population in the subjects of the far Eastern Federal District in 2016–2018 | Abstract similar documents |
| A. V. Veselov, V. V. Omelyanosvkiy, Yu. A. Shelygin, A. V. Vitko, V. N. Kashnikov, N. V. Tashkinov, T. V. Shkurko, A. I. Moskalev, A. A. Serbina | ||
| "... of the FEFD did not change significantly in 2016-2018, it was 0.7 per 100 thousand population. An extremely ..." | ||
| Vol 16, No 1 (2023) | Development of a verified osteoarthritis risk scale based on a cross-sectional study of clinical and anamnestic parameters and pharmacological anamnesis of patients | Abstract similar documents |
| I. Yu. Torshin, А. М. Lila, N. V. Zagorodniy, А. G. Nazarenko, О. N. Tkacheva, Е. N. Dudinskaya, L. I. Alekseeva, Е. А. Taskina, I. V. Sarvilina, О. А. Shavlovskaya, A. B. Danilov, Т. B. Minasov, А. N. Galustyan, S. I. Malyavskaya, А. N. Gromov, Е. Yu. Egorova, L. V. Vasilyeva, E. F. Evstratova, I. V. Gogoleva, L. E. Fedotova, М. I. Udovika, V. A. Maximov, А. S. Povzun, О. А. Gromova | ||
| "... the topological theory of pattern recognition were used. Results. Based on the analysis of the sample, a 100 ..." | ||
| Vol 18, No 1 (2025) | The effectiveness of using artificial intelligence in clinical medicine | Abstract similar documents |
| D. I. Korabelnikov, A. I. Lamotkin | ||
| "... effectiveness: accuracy ranged from 49% to 99%, sensitivity from 42% to 100%, and specificity from 48% to 100 ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology ..." | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... to the reproduced AA (up to 100% replacement of reference medications), the costs would remain to be higher than ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... -consumptive than the kA treatments. even if the treatments were switched to the reproduced AA (up to 100 ..." | ||
| Vol 14, No 1 (2021) | Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District | Abstract similar documents |
| M. S. Soboleva, E. E. Loskutova | ||
| "... , Sakhalin Region, Amur Region (n=100) was carried out. The calculation of the monthly cost of therapy ..." | ||
| Vol 14, No 4 (2021) | Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region | Abstract similar documents |
| А. V. Sokolov, О. V. Reshet’ko | ||
| "... for 90% of all antithrombotic drugs at the outpatient stage – 99.02% in 2011, 93.08% in 2012, 58 ..." | ||
| Vol 7, No 3 (2014) | MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN | Abstract similar documents |
| V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan | ||
| "... of 100 patients if the test's sensivity and specificity were 100% and prevalence of LTBI was 20%. When ..." | ||
| Vol 12, No 3 (2019) | Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings | Abstract similar documents |
| O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev | ||
| "... and discussion. For antimicrobial agents of interest, the NDDD (Number of DDD) per year, and the NDDD/100 bed ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... of April 26, 2012 № 403. Calculation was performed based on the data of registered patients with orphan ..." | ||
| Vol 11, No 1 (2018) | Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) | Abstract similar documents |
| O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov | ||
| "... of the disease. It is important to note that the treatment standard was adopted in 2012. Since then, a number ..." | ||
| Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
| I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
| "... = 30) received chondroitin sulfate, 100 mg in 1 ml (Chondroguard® , Sotex, Russia), i /m, every other ..." | ||
| Vol 13, No 3 (2020) | Comparative analysis of antipsychotic drug consumption for inpatient schizophrenia treatment: a retrospective study with 5-year follow-up | Abstract similar documents |
| L. B. Vaskova, M. V. Tiapkina, E. V. Mikhaylenko | ||
| "... was characterized by alternating declines and rises (from 154.49 to 208.09 NDDD/100 bed-days). The consumption ..." | ||
| Vol 16, No 2 (2023) | Pharmacoepidemiological and drug interaction analysis in the treatment of chronic renal and hepatic failure | Abstract similar documents |
| O. V. Zhukova, D. S. Fokina, O. V. Ruina, M. V. Khazov | ||
| "... ” was calculated using DDD per 100 bed-days. ABC analysis was used to estimate the costs of drug groups in therapy ..." | ||
| Online First | Antitumor effects of vitamin B12 in vitro, in vivo, in silico | Abstract similar documents |
| O. A. Gromova, D. E. Frolova, I. Yu. Torshin, M. V. Filimonova, M. A. Sorokina, I. A. Reyer, O. A. Limanova, L. E. Fedotova, L. A. Maiorova | ||
| "... cells at high concentrations (100–200 µg/l, IC50~100 nM). Experimental animals with an in vivo LLС model ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
| R. I. Yagudina, M. M. Murashko | ||
| "... was carried out from the perspective of health care facilities. The budget impact analysis shown that the 100 ..." | ||
| Vol 10, No 2 (2017) | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA | Abstract similar documents |
| N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov | ||
| "... / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients. Conclusion ..." | ||
| Vol 16, No 2 (2023) | Analysis of social and economic aspects of using prolonged forms of opioid analgesics for the treatment of chronic pain syndrome in cancer patients | Abstract similar documents |
| E. A. Pyadushkina, E. V. Derkach, A. V. Palekhov | ||
| "... of achieving pain control – risk ratio (RR) 0.88 (95% confidence interval (CI) 0.78–1.00), frequency of using ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... lipoprotein cholesterol (LDL-C) on statin therapy, and the scenario with 100% compliance to statin therapy ..." | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... ) and cardiovascular causes by 2.45 cases per 100 thousand population provided that 100% of patients with MI ..." | ||
| Vol 17, No 1 (2024) | Chemoreactome screening of aquacobalamin and heptamethyl ester of cyanoaquacobyrinic acid cytotoxic effects on tumor cells with experimental confirmation on BT-474 and A549 cell | Abstract similar documents |
| I. Yu. Torshin, M. V. Filimonova, O. A. Gromova, L. A. Maiorova, M. A. Sorokina, D. E. Frolova, A. N. Gromov, I. A. Reyer | ||
| "... ), and HECСA significantly reduces the survival of BT-474 and A549 tumor cell lines at high concentrations (100 ..." | ||
| Vol 9, No 3 (2016) | DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY | Abstract similar documents |
| M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov | ||
| "... and tamoxifen (95.24% and 100% of the regions of the Russian Federation). Consumption of drugs varied ..." | ||
| Vol 11, No 2 (2018) | Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer | Abstract similar documents |
| G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin | ||
| "... in 15 fractions) whereas 100 patients of the control group were treated by the conventional therapy ..." | ||
| Vol 13, No 4 (2020) | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard | Abstract similar documents |
| I. Yu. Torshin, A. M. Lila, A. V. Naumov, A. Yu. Kochish, L. I. Alekseeva, E. A. Taskina, I. V. Sarvilina, A. N. Galustyan, A. N. Gromov, A. K. Khadzhidis, L. V. Vasilieva, E. F. Yevstratova, M. I. Udovika, O. A. Gromova | ||
| "... Chondroguard (100 mg i.m. first 3 injections, from tie 4th injection - 200 mg i.m., EOD, course 20-30 ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| "... of treating one patient with an average body weight of 88.3 kg and an initial hemoglobin level of 100 g/l ..." | ||
| Vol 14, No 4 (2021) | Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy | Abstract similar documents |
| N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev | ||
| "... . Results. Up to 100 children and 56 adults could be treated with voretigene neparvovec in 2021–2030 ..." | ||
| Vol 16, No 2 (2023) | Providing pharmaceutical consultation to visitors of pharmacy organizations in routine pharmaceutical practice | Abstract similar documents |
| M. S. Soboleva | ||
| "... study involving a simulated secret patient in 100 pharmacy organizations in the city of Khabarovsk ..." | ||
| Vol 16, No 3 (2023) | Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, T. N. Ermolaeva, K. A. Kokushkin | ||
| "... .4 persons per 100 thousand population). Using quadruple therapy in 1000 target patients during the first ..." | ||
| Vol 16, No 4 (2023) | Sales of antitumor drugs in the retail segment of the Russian pharmaceutical market | Abstract similar documents |
| I. K. Petrukhina, T. K. Ryazanova, E. P. Gladunova, A. M. Lazarev, A. A. Krivova | ||
| "... . The maximum sales in monetary terms per 100 thousand population were noted in the Central, Northwestern ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... practice) to 100% (considered therapy practice) will reduce the budget load for the population of 6 ..." | ||
| Vol 17, No 3 (2024) | Chemoreactomic analysis of the antioxidant properties of vitamin B12 derivatives | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, L. A. Maiorova | ||
| "... exhibited the most pronounced antioxidant properties at lower concentrations (up to 100 µM). At higher ..." | ||
| Vol 18, No 2 (2025) | Chemoreactomic analysis of the drug prototype pilim-1 in comparison with zinc derivatives of nonsteroidal anti-inflammatory drugs | Abstract similar documents |
| P. A. Galenko-Yaroshevsky, I. Y. Torshin, A. N. Gromov, I. A. Reyer, O. A. Gromova, B. A. Trofimov, L. N. Parshina, R. A. Murashko, O. V. Shelemekh, A. V. Zadorozhniy, V. L. Popkov, A. V. Zelenskaya, I. B. Nektarevskaya, A. V. Sergeeva, A. V. Uvarov, Yu. V. Tovkach, I. V. Sholl | ||
| "... dose of 100 mg/kg was estimated at 35% (compared to 75% with other molecules). Compared to other zinc ..." | ||
| Vol 10, No 4 (2017) | PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... if the prevention is increased to 100%. Simulated scenario 2 allows for achieving even more significant results ..." | ||
| Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... proposed a mathematical model for DN progression in groups of patients who received canagliflozin (100 mg ..." | ||
| 1 - 50 of 55 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
